Oxford Biomedica plc (LSE:OXB) shares fell 1.33% to 520p in the latest market screen, a decline of 7p for the cell and gene therapy contract development and manufacturing organisation (CDMO).
There was no new company announcement behind the move. The shares eased amid broader market weakness, as investors reduced exposure to growth and higher-risk sectors during a global risk-off session.
Key Highlights
In its interim results on 22 September 2026, OXB reported first-half revenue of around £80 million, up around 9% to 10%, and a record 17 new client wins, with four more signed after the period end, bringing its portfolio to 59 client programmes and 50 clients.
The company reiterated its guidance, expecting FY26 revenue of £180 million to £200 million and a mid-single-digit EBITDA margin excluding one-off costs. It expects FY27 revenue growth of 25% to 30%.
The FY26 guidance had been cut in August from £220 million to £240 million, due to changes in customer ordering patterns, client programme delays and a six-month postponement in the ramp-up of its Durham, North Carolina facility.
OXB has around £168 million of FY26 revenue covered by contracted orders and a revenue backlog of around £199 million.
About Oxford Biomedica plc
Oxford Biomedica plc (LSE:OXB) is a global quality and innovation-led CDMO specialising in cell and gene therapies. It manufactures viral vectors, including lentiviral and AAV vectors, which are used to deliver genetic material in advanced therapies.
OXB operates facilities in the UK, Europe and the US, including its newly operational Durham, North Carolina GMP manufacturing site.
Its client base includes pharmaceutical and biotech companies developing therapies for cancer, genetic diseases and other conditions.
Why Is LSE:OXB Down Today?
The 1.33% decline to 520p reflects broad market weakness rather than company-specific news.
Biotech and healthcare services stocks can be sensitive to risk appetite and interest rate expectations, which were affected by rising oil prices and inflation concerns.
The shares remain well below their 52-week high of around 950p, following the August guidance cut.
Key Reasons Behind the Downtick
The first factor is market risk aversion.
The second factor is lingering caution after the guidance cut in August.
Third, profitability remains low, with a mid-single-digit EBITDA margin expected in FY26.
Fourth, gross margin fell to 37% from 43% in the first half due to mix effects.
Key Growth Catalysts
The most important catalyst for LSE:OXB is FY27 revenue growth of 25% to 30%.
Record client wins expand the future revenue base.
The Durham facility is now online, expanding US capacity.
Double-digit EBITDA margins are targeted for 2027.
Risks
The main risk for LSE:OXB is revenue volatility from client programme timing.
Execution risk, funding conditions for biotech clients and competition are also important.
Valuation
At 520p, OXB trades below the analyst average target of around 703p, according to Investing.com. Deutsche Bank downgraded to Hold with a 595p target, while Stifel and RBC retain Buy ratings.
Capital Returns
OXB does not pay a dividend, as it reinvests in growth.
What Investors Should Watch Next
Investors will watch new contract wins, the Durham ramp-up and full-year results.
Overall, the 1.33% decline in LSE:OXB to 520p reflects market weakness and lingering caution after this year's guidance cut.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...